Transdermal vs oral MHT: What difference does the treatment route make to CVD risk?
Authors say the administration method had varying effects on women's odds of a cardiovascular event.
Researchers have assessed the cardiovascular risks for a variety of hormone therapies for postmenopausal women, finding ‘diverse effects’ for different treatments.
For example, postmenopausal women who use oral oestrogen-progestogen therapy have an increased risk of heart disease and VTE within two years of starting treatment, the data suggest.
And using tibolone was associated with an increased risk of heart disease, MI and stroke but not VTE, say the Australian and Swedish researchers.
The team said theirs was the first large study to evaluate the ‘diverse effects’ for different forms of contemporary menopausal hormone therapy (MHT) according to the route of administration and combination of hormones.
